Upon reexamination, the European Medicines Agency has made a U-turn on Eisai and Biogen’s Alzheimer’s disease drug Leqembi. | ...

After re-examining its initial opinion, EMA’s human medicines committee, or CHMP, has recommended granting a marketing authorisation to Leqembi for treating mild cognitive impairment or mild dementia ...

Ema Stokholma, engaged every day with the program “Radio 2 Social Club”, is a guest today on La Volta Buona, the program ...

The European Union's drugs regulator reversed its decision to block the Alzheimer's drug lecanemab, a treatment aimed at ...

Europe's medicines watchdog on Thursday partially approved a marketing request for a long-awaited new treatment for Alzheimer ...

A Government Exports minister has acknowledged the pivotal role East Midlands Airport (EMA) plays in driving regional growth ...

Stockhead’s Sarah Hughan sits down with Brazilian Critical Minerals (ASX:BCM) managing director Andrew Reid to get the short ...

A key regulatory committee sided against the drug this summer. But an appeal from Eisai appears to have worked, teeing ...

EUR/AUD tests an immediate barrier at a nine-day EMA at 1.6308 level near the upper boundary of the descending channel.

Net Loss of EMA India reported to Rs 0.11 crore in the quarter ended September 2024 as against net loss of Rs 0.11 crore during the previous quarter ended September 2023. There were no Sales reported ...

Biogen’s stock rose 1% Thursday, after Europe’s pharmaceutical regulator issued a positive opinion on the Alzheimer’s disease ...

This is despite no scientific proof that there is alien life on other planets. University of Birmingham philosopher Dr Ema ...